Skip to main content
Premium Trial:

Request an Annual Quote

Genelex, Mental Health Connections Ink Merger

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genelex and Mental Health Connections announced today that have merged their firms, creating a new company focused on personalized prescribing services.

The merger combines Seattle-based Genelex's DNA Drug Sensitivity testing products, which have been designed to help physicians predict response to certain over-the-counter and prescription drugs, with MHC's GeneMedRx drug and gene interaction software. Genelex also offers paternity testing services and ancestry DNA testing.

Financial terms of the agreement were not disclosed.

The firms will operate under the Genelex name, with Genelex CEO Howard Coleman maintaining that title for the combined entity. Robert Patterson, principal of Lexington, Mass.-based MHC, will serve as chief informatics officer.

Coleman said in a statement that the combination of the firms' technologies "is a major advance in our ability to solve the epidemic of medication-driven adverse drug reactions, interactions, and treatment failures."

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.